生物类似药显露头角医药研发成本不断攀升——2016年重磅新药研发热点回眸

 2016年，全球医药市场规模超过1万亿美元，医药研发成本不断攀升，小分子新药获批数量日益降低，抗肿瘤药物、孤儿药研发势头依旧不减。随着生物药专利悬崖逐渐显现，生物类似药崭露头角。遴选了2016年上市的部分重磅新药，盘点了抗感染、抗肿瘤、中枢神经系统等领域的新药研发进展，回顾了2016年国内药学领域的相关热点事件。

Biosimilar show a good development prospect,while drug research and development cost is spiralling

In 2016, the global pharmaceutical market size reached more than 1 trillion US dollars. In spite of the rise of pharmaceutical research & development cost and the decline of approval number of small molecular drugs, the research and development of anti-tumor drugs and orphan drugs remained robust last year. On the other hand, with the coming patent cliff of biological products, biosimilars were emerging. In this paper, we select some of the blockbusters in 2016, covering the frontiers of drug development for anti-infection, antitumor, central nervous system and other areas, and provide a review of 2016 domestic hotspots in pharmaceutical industry.